Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France. Show More...
-
Website https://www.inventivapharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 2.89 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -0.71 -0.75 -0.88 -0.7 -1.23 -1.64 -1.28 -1.28 Dividends EUR Payout Ratio % * Shares Mil 10.0 10.0 10.0 10.0 16.0 21.0 24.0 24.0 Book Value Per Share * EUR 4.33 3.53 1.36 1.35 Free Cash Flow Per Share * EUR -1.16 -1.2 -1.71 Return on Assets % -8.19 -9.35 -13.2 -12.88 -27.96 -43.61 -44.19 -44.19 Financial Leverage (Average) 1.48 1.42 1.42 1.37 1.16 1.3 1.38 1.38 Return on Equity % -12.09 -13.56 -18.72 -17.95 -34.55 -53.53 -58.68 -58.68 Return on Invested Capital % -12.1 -13.85 -18.87 -18.02 -34.62 -53.35 -58.79 -58.79 Interest Coverage Current Ratio 2.88 3.88 3.69 4.8 7.64 4.75 3.53 3.53 Quick Ratio 2.56 3.26 3.04 3.29 6.87 3.82 2.65 2.65 Debt/Equity 0.010 0.010